Okyo Pharma has announced that screening and recruitment has been initiated for a phase 2 trial of OK-101 to treat neuropathic corneal pain, with plans to enroll 48 patients, according to a company press release.
“The initiation of this trial of topically applied OK-101 to treat [neuropathic corneal pain (NCP)] marks a significant step forward for the company, as we have been laser focused on moving this drug candidate into a clinical trial to treat NCP over the last 12 months,” Gary S. Jacob, PhD, Okyo’s CEO, said in the (Read more...)